These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25542874)

  • 1. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
    Camacho Á; Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy].
    Sebastián Mde L; Pardo OB; Ortega FP
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():12-7. PubMed ID: 25542870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
    Rolón MJ; Figueroa MI; Sued O; Cahn P
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
    Aguirrebengoa K
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():2-6. PubMed ID: 25542868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
    Tasias M; Aldeguer JL
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lopinavir/ritonavir in human immunodeficiency virus-infected women].
    Téllez MJ
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():22-5. PubMed ID: 25542872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The "induction-maintenance" strategy].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():8-11. PubMed ID: 19572438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M; Norton M
    HIV Clin Trials; 2006; 7(5):237-45. PubMed ID: 17162317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
    Moltó J; Clotet B
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.
    Gatell Artigas JM; Arribas López JR; Lázaro Y de Mercado P; Blasco Bravo AJ
    Enferm Infecc Microbiol Clin; 2016; 34(7):427-30. PubMed ID: 25749416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.
    Kanters S; Socias ME; Paton NI; Vitoria M; Doherty M; Ayers D; Popoff E; Chan K; Cooper DA; Wiens MO; Calmy A; Ford N; Nsanzimana S; Mills EJ
    Lancet HIV; 2017 Oct; 4(10):e433-e441. PubMed ID: 28784426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.